Background/Aims: Regional hypoxia promptly develops after trauma because of microvascular injury and increased oxygen consumption. This acute hypoxia plays a positive role in early skin wound healing. One of the mechanisms underlying the beneficial effects of acute hypoxia on wound healing may be increased hypoxia-inducible factor-1 (HIF-1α) expression. HIF-1α may affect the wound-healing process through many aspects, including angiogenesis, metabolism, and extra-cellular matrix synthesis and remodelling. Epidermal stem cells (EpSCs) are important participants in wound repair; however, whether these cells are regulated by hypoxia is unclear. This study aimed to elucidate the regulatory mechanism by which hypoxia acts on EpSCs. Methods: CCK8 assays, western blots and live cell station observation were employed to compare the viability, proliferation and motility of EpSCs cultured under normoxic conditions (21% O 2 ) with those cultured under hypoxic conditions (2% O 2 ). Moreover, we used FG-4592 (a prolyl hydroxylase inhibitor that stabilizes HIF-1α in normoxia), KC7F2 (a selective inhibitor of HIF-1α transcription) and siRNA against HIF-1α to regulate HIF-1α expression. Results: Acute hypoxia caused EpSCs to switch from a quiescent state to an activated state with higher viability and motility, as well as an earlier proliferation peak. We demonstrated that the HIF-1 signalling pathway mediated hypoxiainduced activation of EpSCs. Finally, the in vivo experiments showed that exogenous FG-4592 effectively accelerates wound healing, shortens healing times and even induces epidermal hyperplasia. Conclusion: This study demonstrated that both hypoxia and exogenous FG-4592 improve EpSC proliferation and motility by stabilizing HIF-1α, and its results suggest that HIF-1α is an important target through which wound healing can be accelerated and that FG-4592 is a promising new drug for wound repair.
FG-4592 Accelerates Cutaneous Wound Healing by Epidermal Stem Cell Activation via HIF-1α Stabilization

Introduction
Cutaneous wounds resulting from conditions such as trauma, burns, surgery, and diabetes are common clinical problems [1] . However, how wound healing is effectively promoted, as well as how chronic refractory wounds are treated, is not well understood.
We and others previously demonstrated that following acute injury, the skin wound microenvironment becomes more hypoxic due to vascular disruption and high oxygen consumption by the cells at the edges of the wound [2] [3] [4] . In contrast to hypoxia-induced injury [5, 6] , this acute hypoxia plays a positive role in the early stage of wound healing, which induces the production of numerous cytokines, including vascular endothelial growth factor (VEGF), transforming growth factor-b (TGF-b), and platelet-derived growth factor (PDGF), in the wound microenvironment [2] . Impaired responses to tissue hypoxia are believed to be a major factor responsible for diminished wound healing in chronic wounds [7] [8] [9] [10] [11] [12] . Therefore, elucidating the molecular mechanism underlying cell responses to hypoxia may facilitate the development of strategies for promoting wound healing.
Epidermal stem cells (EpSCs), which are adult stem cells, reside in the basal layer of the interfollicular epidermis [13] . EpSCs and their daughter cells, which are also known as keratinocytes, play an essential role in re-epithelialization by first migrating from their niche towards the wound and then undergoing proliferation and differentiation. Previous studies have shown that biological processes, such as pregnancy, lactation [14, 15] , hypoxia [16] and circadian rhythms [17] , can impact stem cells. In this study, we focused on how EpSCs respond to hypoxia. Hypoxia triggers tumour growth [18] [19] [20] . Moreover, the proliferation and migration of stem cells are somewhat similar to the growth and metastasis of tumour cells. Those factors inspired us to explore how hypoxia affects EpSCs.
Hypoxia-inducible factor-1 (HIF-1), a heterodimeric transcription factor complex, has been recognized as a master regulator of hypoxia for more than 20 years [21] . HIF-1β protein levels are relatively constant; however, HIF-1α is hydroxylated on conserved proline residues under normoxic conditions, which results in von Hippel-Lindau protein E3 ubiquitin ligase recruitment and immediate proteasomal degradation. This prolyl hydroxylation is mediated by an enzyme family of HIF-prolyl hydroxylases (prolyl-4-hydroxylation domain (PHD) proteins), whose activity is dependent on dioxygen, ferrous iron and 2-oxoglutarate [22] . PHDs are less active in hypoxic conditions, in which HIF-1α translocates to the nucleus and dimerizes with HIF-1β, which allows the complex to bind to the hypoxia response elements (HREs) in the regulatory sequences of several genes vital to cell survival [23] .
HIF-1α affects the wound-healing process in many ways, as it affects the expression of multiple angiogenic growth factors, cell motility, and the recruitment of endothelial progenitor cells [2] . Moreover, recent studies using gene-knockout methods have demonstrated that both PHD-2 [24] and HIF-1α [25] have an effect on wound healing.
In light of the evidence linking HIF-1α to wound healing, new drugs that manipulate its expression and function are needed. FG-4592, a novel prolyl hydroxylase inhibitor, is currently in phase three clinical trials regarding the treatment of renal anaemia in patients with chronic kidney disease [26] . In recent years, some studies have shown that FG-4592 stabilizes HIF-1α and increases tolerance to hypoxia, thereby improving the prognosis of many diseases, such as renal anaemia [26, 27] , spinal cord injury [21] , and retinal disease [28, 29] . However, there have been no attempts to investigate the role of FG-4592 in wound healing. Accordingly, the present study was designed to analyse whether treatment with the novel PHD inhibitor FG-4592 accelerates wound healing in mice and promotes EpSCs proliferation and motility.
Materials and Methods
Ethics statement
All animal-based investigations were designed and performed in accordance with the Guide for the Care 
Culture and characterization of mouse EpSCs
Mouse EpSCs were isolated from newborn (aged 0-2 days) mouse skin, according to a method described previously [1] . Briefly, the mouse skin tissues were incubated in 0.5% dispase II in 0.9% NaCl solution overnight at 4°C. The epidermal sheet was carefully separated from the dermis, minced, and then digested in 0.5% trypsin in phosphate-buffered saline (PBS) for 5-10 minutes at 37°C. The epidermal suspension was subsequently gently agitated to create a single-cell suspension. Trypsin was inactivated in calcium-free RPMI 1640 medium containing 10% chelexed FBS. The suspension was filtered through a 70-μm cell strainer and then centrifuged at 1000 rpm for 5 minutes. The complete medium for the mouse EpSCs contained defined keratinocyte serum-free medium (DK-SFM, 10744-019; Gibco), calcium chloride (0.05 mM), mouse epidermal growth factor (10 ng/ml, 354001; BD), cholera toxin (10 -10 M, C9903; Sigma) and penicillin and streptomycin solution (100 IU/ml, 15140122; Gibco). The cells were seeded in plates or flasks coated with 100 μg/ml type IV collagen (C5533; Sigma) at a density of 10 5 cells/cm 2 and were allowed to adhere for 15 minutes at 37°C. The non-adherent cells were subsequently discarded, and the rapidly adhering cells were cultured in complete medium at 37°C in 5% CO 2 .
EpSC characterization was performed according to the methods described by Kaur [30] . After the cells were cultured for 3 days, they were digested and stained with FITC-conjugated CD71 (561936; BD) and PEconjugated CD49f (555736; BD) antibodies. Flow cytometry data were acquired using an Attune Acoustic Focusing Cytometer (Applied Biosystems, Life Technologies, CA, USA), and the data were analysed using FlowJo software (Tree Star Incorporation, USA).
Hypoxia treatment
Hypoxic conditions were established using a Forma Series II Water Jacket CO 2 incubator (model: 3131; Thermo Scientific), with which we could precisely control oxygen levels and temperature. The hypoxic conditions were generated at 37°C in 5% CO 2 , and the designated oxygen content was balanced with N 2 . All of the media used in the hypoxia experiments were preincubated in chambers with the designated oxygen content overnight.
Cell proliferation and viability assessment by CCK8 assay
EpSCs were seeded in 96-well cell culture plates. Cell proliferation was determined in each group using Cell Counting Kit-8 (CCK-8; Beyotime, China), and the absorbance was measured at 450 nm using a microplate reader (Thermo, USA).
Western blot analysis
The cells were washed with ice-cold PBS and harvested on ice. The protein concentration of the resulting lysates was determined using a RCDC protein assay kit (Sigma, USA). A prestained standard protein molecular weight marker and the protein samples were subsequently loaded into wells and separated by 8% SDS-PAGE. The blots were then transferred to polyvinylidene difluoride (PVDF) membranes by electroblotting. The membranes were blocked with 5% nonfat dried milk or bovine serum albumin (BSA) and then incubated with the following primary antibodies overnight at 4°C: rabbit anti-PCNA (1:2000 dilution; Proteintech, USA), rabbit anti-HIF-1α (1:1000 dilution; Proteintech, USA) and mouse anti-β-actin (1:5000 dilution; Abcam, UK). The membranes were then incubated with horseradish peroxidaseconjugated secondary IgG (1:5000 dilution; Proteintech, USA), which was used as the secondary antibody. The results were analysed using a ChemiDoc imaging system (Bio-Rad, USA).
Cell motility assay and quantitative analysis
For the cell motility assays, EpSCs were seeded in 24-well plates. After each group received the appropriate treatment, the cells were evaluated by time-lapsed imaging with a Zeiss imaging system (Carl Zeiss Meditec, Jena, Germany) equipped with a CO 2 -and temperature-controlled chamber. Images were acquired every 5 minutes for 3 h. The trajectories of the cells were subsequently determined by tracing the positions of the cell nuclei at frame intervals of 5 minutes using NIH ImageJ software. The velocity (μm/h) of each cell, which reflects cell motility, was calculated as the total length (μm) of each trajectory divided by time (h). 
Cell treatments
According to previous research results [4] , the oxygen tension in the wound edge is approximately 10 mmHg (equivalent to 2% oxygen concentration). To simulate the hypoxic microenvironment of wound healing, we chose a 2% oxygen concentration as the hypoxic condition in cell experiments. EpSCs in the hypoxia group were placed into a hypoxic incubator with an oxygen concentration of 2% at 24 h after seeding. The cells in both the normoxia and hypoxia groups were then harvested or tested at the indicated time points.
For the HIF-1α regulation experiments, 5 μM or 10 μM FG-4592 (S1007; Selleck) or KC7F2 (S7946; Selleck) was added to the medium at 24 h after the cells were seeded (at which time they had reached approximately 30%-50% confluence). The culture plates in the hypoxia group were placed into another hypoxic incubator with an oxygen concentration of 2%. The EpSCs were harvested or tested after 24 h of treatment.
To specifically inhibit HIF-1α expression, we purchased HIF-1α siRNA and a negative-control siRNA (siRNAcon) from Shanghai GenePharma, Co. Ltd. (Shanghai, China). The EpSCs were seeded in plates or flasks, according to the experiment. When the cells reached approximately 30%-50% confluence, they were transfected with HIF-1α siRNA or siRNAcon for 6 h, according to the manufacturer's protocol, after which they were cultured in serum-free medium for 24 h. The cells were subsequently treated with FG-4592 or hypoxia at 12 h before harvesting or further testing.
Animal model
Adult male BALB/c mice (10 to 12 weeks of age, 20±2 g) were prepared for surgery (n=8). These mice were randomly divided into the following two groups: a control group and an FG-4592 group. Two 4-mm full-thickness excisional wounds extending through the panniculus carnosus were made on the dorsum of each mouse after depilation, as previously described [31] . A donut-shaped (inner diameter, 7 mm; outer diameter, 12 mm) self-adhesive silicone splint (3 M, Shenzhen, China) was placed and fitted to the skin such that the wound was centred within the splint. The advantages of this animal model include easy operation, no new damage to skin around the wound, and a reference for measuring the size of the wound is provided. The animals were then housed individually.
FG-4592 (S1007; Selleck) was first prepared as a 50 mg/ml stock solution, according to a method described previously [29] , after which it was diluted to a concentration of 1 mg/ml in sterile PBS and stored at -80°C. FG-4592 and PBS were intraperitoneally administered to the mice in the FG-4592 and control groups, respectively, at a dose of 10 mg/kg daily.
Digital imaging was preformed every other day until wound closure. The time to wound closure was defined as the time at which the wound bed had completely re-epithelialized and filled with new tissue. Wound area was quantified by tracing the wound margins and was calculated as a percentage of the original wound area using ImageJ software.
Statistical analysis
Statistical comparisons were performed by Student's t test or one-way ANOVA using GraphPad Prism 6.0 software (GraphPad Software Inc.). The data are presented as the mean ± standard error of the mean (SEM). In all cases, P<0.05 was considered statistically significant.
Results
Acute hypoxia induces EpSCs activation
To explore how oxygen tension affects EpSCs, we first used CCK-8 to detect EpSC viability. Interestingly, EpSCs incubated in hypoxic conditions (2% O 2 ) displayed better viability than cells incubated in normoxic conditions (Fig. 1A) . This advantage appeared during the first 24 h of the experiment. Western blotting showed that PCNA expression was much higher in the hypoxia group than in the normoxia group at 12 h after hypoxia treatment and slightly higher in the hypoxia group than in the normoxia group at 24 h after hypoxia treatment. (Fig.  1 B) . Hypoxia had a positive effect on cell motility, as it expanded cell ranges of movement (Fig. 1 C) and increased EpSC velocities (Fig. 1 D) . These results indicate that acute hypoxia
activates EpSCs by promoting cell proliferation and motility.
HIF-1α is involved in hypoxiainduced EpSC activation
We initially detected the expression of HIF-1α, which served as a positive control, to determine whether hypoxia treatment was effective (Fig. 1  B) . We then determined whether HIF-1α mediates hypoxia-induced increases in EpSC proliferation and motility. We used FG-4592 (a prolyl hydroxylase inhibitor that stabilizes HIF-1α in normoxia) and KC7F2 (a selective inhibitor of HIF-1α transcription) to regulate HIF-1 signalling. A CCK-8 assay showed that FG-4592 increased EpSC cell viability in normoxia and that KC7F2 decreased EpSC viability in a dose-dependent manner both in normoxia and in hypoxia ( Fig. 2A) . Western blot showed that FG-4592 increased 
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The movement trajectories of the EpSCs in each group were recorded by a Zeiss imaging system. The velocity of each group is shown as the mean±SD. N, normoxia; H, hypoxia; *, P<0.05 versus the normoxia group; #, P<0.05 versus the hypoxia group. 2B ) and thus had the same effect as hypoxia treatment. In contrast, KC7F2 decreased HIF-1α and PCNA expression (Fig. 2C) . Moreover, FG-4592 promoted EpSC motility in normoxia, while KC7F2 reversed hypoxia-induced increases in cell motility ( Fig. D and E) . The above data demonstrate HIF-1α plays an important role in hypoxia-induced EpSC activation.
FG-4592 simulates the effects of hypoxia on EpSCs specifically through HIF-1α stabilization
FG-4592 simulates the effects of acute hypoxia; however, whether it acts specifically through HIF-1α stabilization was unknown. Therefore, we used HIF-1α siRNA (siRNA against HIF-1α) to downregulate HIF-1 signalling. A CCK-8 assay showed that HIF-1α siRNA effectively reversed hypoxia-and FG-4592-induced increases in EpSC viability (Fig. 3A) . Western blotting showed that HIF-1α siRNA also reduced PCNA expression under both FG-4592 treatment (Fig. 3B ) and hypoxic conditions (Fig. 3C) . Cell motility assays and quantitative analysis showed that HIF-1α siRNA inhibited the cell motility increases induced by FG-4592 and hypoxia ( Fig. 3D and E) . These results reveal that FG-4592 exerted its effects mainly through HIF-1α stabilization.
FG-4592 effectively accelerates wound healing in vivo
We used a humanized wound-healing model that heals through granulation tissue and re-epithelialization to test in vivo wound closure rates. We noted a significant difference in the wound closure rate between the control and FG-4592 groups on days 2, 4, 6, and 8 post-injury ( Fig. 4A and B) . The wounds on the mice in the control group (intraperitoneally injected with PBS) closed on post-injury day 9.88±0.55, whereas the wounds on FG-4592-treated mice (intraperitoneally injected with FG-4592) healed on post-injury day 8.13±0.35 (*P<0.05) (Fig. 4C) . Moreover, the average neo-epidermis length in the mice in the control group was significantly shorter than that in the mice in the FG-4592 group ( Fig. 4D and E Cellular Physiology and Biochemistry
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PCNA expression in the wound tissue on day 10 post-injury (three independent samples from each group). Western blotting and quantitative analysis showed that FG-4592 effectively increased HIF-1α and PCNA expression in the FG-4592-treated group compared with the control group (Fig. 5C ) and that the differences in HIF-1α and PCNA expression between the two groups were statistically significant ( Fig. 5D and E) . These results confirmed that FG-4592 promotes cell proliferation but also indicate that HIF-1α overexpression results in epidermal hyperplasia.
Discussion
In this study, we found that acute hypoxia caused EpSCs to switch from a quiescent state to an activated state with higher viability and motility, as well as an earlier proliferation peak. We investigated the mechanism underlying this phenomenon and found that HIF-1α was involved in the process. Given that local oxygen tension is affected by many factors and is not easy to regulate, HIF-1α may be used as a preferred target to induce EpSCs to participate in wound healing. We also demonstrated that FG-4592 promoted EpSC proliferation and motility via HIF-1α stabilization and accelerated wound healing in vivo. Our findings show that HIF-1α is an important target for accelerating wound healing and that FG-4592 is a promising new drug for wound care (Fig. 6) .
Wound healing is a complex multistage process that requires the spatial and temporal orchestration of cellular and non-cellular components [23] . Hypoxia has been recognized as one of the prominent micro-environmental factors in tissue injury [32] and wound healing for decades [3, 33] ; however, the effect of hypoxia on wound healing remains controversial [23, [34] [35] [36] [37] . As skin seed cells, EpSCs and their offspring undergo slow, rhythmic processes of proliferation and differentiation in physiological conditions. After injury, more EpSCs are activated and participate in wound healing. We compared EpSCs cultured in normoxia with those cultured in hypoxia and found that EpSCs cultured in hypoxia (2% O 2 ) had higher viability and motility, a broader range of movement, and even an earlier proliferation peak than EpSCs cultured in normoxia (Fig. 1) . Our findings suggest that acute hypoxia may be one of the factors that triggers the switching of EpSCs from a quiescent state to an active state. Hypoxic responses, which are mediated mainly by a master oxygen homeostasis transcription factor, HIF-1, have been shown to be critically involved in many important life processes, including wound healing [2, 23] . However, whether HIF-1 mediates the hypoxic regulation of EpSC activation is still poorly understood. FG-4592 (a prolyl hydroxylase inhibitor that stabilizes HIF-1α in normoxia) [21, 29] and KC7F2 (a selective inhibitor of HIF-1α transcription) [38] were used to regulate HIF-1α expression. We found that the HIF-1 signalling pathway plays an important role in EpSC activation (Fig. 2) .
Gaining a better understanding of this mechanism may provide insights necessary for the development of a novel therapeutic strategy for accelerating wound healing. Regarding EpSC activation, HIF stabilization by hypoxia or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) induces the activation of a group of target genes, including genes related to cell proliferation [39] , viability and motility [2, 4, 40] . Stabilizing HIF with a small-molecule HIF-PHI may be an innovative therapeutic approach to wound treatment. More importantly, FG-4592 is a first-class, potent HIF-PHI and was shown to be safe in a clinical trial regarding chronic kidney disease [27] . Given that FG-4592 stabilizes both HIF-1 and HIF-2, we used siRNA HIF-1α to determine whether hypoxia-and FG-4592-induced EpSC activation are HIF-1 signalling-dependent processes (Fig. 3) .
In our in vitro study, FG-4592 was used to treat mice with full-thickness excisional wounds. The drug dose was determined according to a recent study, which revealed that FG-4592 plays a role in the prevention of retinopathy of prematurity [29] . Intraperitoneal injection of FG-4592 effectively increased HIF-1α expression in skin (Fig. 5C-E) and accelerated the wound closure (Fig. 4) . More interestingly, the mice in the FG-4592 group had a thicker neo-epidermis than the mice in the control group (Fig. 5A and B) . We inferred that this epidermal thickening had two causes. First, the wound-healing process ended as the oxygen tension normalized [4] , indicating that the epidermal thickening was due to the effects of hypoxia on EpSCs. Second, exogenous FG-4592 kept the EpSCs in an activated state instead of a quiescent state. Coincidentally, another study revealed that ageing K14-Cre/ HIF-1α flox/flox mice displayed a phenotype characterized by epidermal thinning and dermal atrophy [25] . These results confirm that HIF-1α is an important positive regulator of wound healing, especially the re-epithelialization process, in which epidermal stem cells and their offspring are deeply involved.
For burn patients, epidermal thickening is doubtless a good thing because a thickened epidermis is abrasion resistant and displays less blistering. Although concerns exist regarding the possibility that epidermal thickening promotes tumourigenesis, it is worth noting that epidermal thickening had no clear tumourigenic effects in PHD-2 knockout mice [24] . FG-4592, a prolyl hydroxylase inhibitor, is now in phase three clinical trials regarding the treatment of renal anaemia in patients with chronic kidney disease [26] . Moreover, recent studies reported FG-4592 can be applied in the treatment of retinal disease [28, 29] and spinal cord injury [21] . These studies indicate that FG-4592 has immense therapeutic potential in HIF-1 signalling-related disease. However, additional clinical trials on the safety and efficacy of FG-4592 in wound care are urgently required so that this therapeutic strategy can be moved from the bench to the bedside.
Conclusion
Taken together, our results illustrate that HIF-1 signalling contributes to hypoxiainduced activation of EpSCs at the wound edge, which accelerates wound healing. Injection of exogenous FG-4592 simulated the positive effect of hypoxia on the switching of EpSCs from a quiescent state to an activated state. Understanding this mechanism may enable the development of a novel and precise wound care strategy.
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